Evaluating long-term outcomes in patients with operable solitary liver tumors
Ten-Year Outcomes of Operable Solitary Hepatocellular Carcinoma Patients: Impact of Tumor Size Over 6.5 cm and Microvascular Invasion
Chang Gung Memorial Hospital · NCT06628661
This study looks at how the size of liver tumors and certain cancer features affect survival and recurrence in patients who have had surgery for liver cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Chang Gung Memorial Hospital (other) |
| Locations | 1 site (Taoyuan) |
| Trial ID | NCT06628661 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the long-term outcomes of patients with operable solitary hepatocellular carcinoma (HCC) by analyzing the impact of tumor size and microvascular invasion on survival and recurrence rates. Researchers will retrospectively examine data collected from the Chang Gung Research Database, focusing on patients who underwent surgery for HCC larger than 6.5 cm. The study will classify patients based on tumor size and microvascular invasion status to evaluate outcomes across different sub-populations. This comprehensive analysis leverages a robust clinical database to provide insights into the factors influencing patient prognosis.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with operable solitary hepatocellular carcinoma.
Not a fit: Patients with non-operable HCC or those with incomplete data regarding tumor size or survival status may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify critical factors that influence survival and recurrence in HCC patients, leading to improved treatment strategies.
How similar studies have performed: Previous studies utilizing similar methodologies have shown promising results in understanding the prognostic factors in hepatocellular carcinoma.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Operable solitary hepatocellular carcinoma Exclusion Criteria: * Not pT1N0M0 or pT2N0M0 * Missing tumor size * Errors in survival/recurrence dates or status
Where this trial is running
Taoyuan
- Chang Gung Medical Foundation — Taoyuan, Taiwan (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hepatocellular Carcinoma, Solitary Mass, Hepatocellular carcinoma, Solitary tumor, Operable, Survival analysis, Tumor size, Microvacular invasion